Cardiovascular high-risk patients - Treat to protect, but whom?

MedGenMed Medscape General Medicine

Volumn 10, Issue SUPPL., 2008, Pages

  Zannad, Faiez ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BENDROFLUMETHIAZIDE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CANDESARTAN; CHOLESTEROL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; PERINDOPRIL; RAMIPRIL; TELMISARTAN; TRANDOLAPRIL; VALSARTAN; CARDIOTONIC AGENT;

ALGORITHM; ANGINA PECTORIS; ARTERY CALCIFICATION; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DRUG EFFICACY; DYSLIPIDEMIA; ELECTROCARDIOGRAPHY; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART VENTRICLE HYPERTROPHY; HIGH RISK PATIENT; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; MICROALBUMINURIA; MONOTHERAPY; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIMARY PREVENTION; PROTEINURIA; REVASCULARIZATION; RISK ASSESSMENT; RISK REDUCTION; SECONDARY PREVENTION; SMOKING; SMOKING CESSATION; CARDIOVASCULAR DISEASE; META ANALYSIS; METHODOLOGY; MORTALITY; PATIENT SELECTION; REVIEW; RISK FACTOR;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; HUMANS; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTORS;

EID: 42549110164     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Mitka M. Heart disease a global health threat. JAMA. 2004;291:2533.
2. Kannel WB: Importance of hypertension as a major risk factor in cardiovascular disease. In: Genest J, Koiw E, Kuchel O, eds. Hypertension: Physiopathology and Treatment. New York: McGraw-Hill; 1977:888-910.
3. Wilson, PW, Kannel WB, Silbershatz H, et al. Clustering of metabolic factors and coronary heart disease. Arch Intern Med. 1999;159:1104-1109.
4. Poulter N. Coronary heart disease is a multifactorial disease. Am J Hypertens. 1999;12:92S-95S.
5. Fagot-Campagna A, Rolka DB, Beckles GLA, et al. Prevalence of lipid abnormalities, awareness, and treatment in U.S. adults with diabetes. Diabetes. 2000;49(suppl):A78-A79.
6. Kannel WB. Bishop Lecture. Contribution of the Framingham Study to preventive cardiology. J Am Coll Cardiol. 1990;15:206-211.
7. Kannel WB. The lipid-atherogenesis connection. 12 questions frequently asked by physicians. Consultant. 1988;28:25-38.
8. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-1053.
9. Doll R, Peto R, Wheatley K, et al. Mortality in relation to smoking: 40 years' observation on male British doctors. BMJ. 1994;309:901-911.
10. Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. BMJ. 1989;298:789-794.
11. Thun MJ, Apicella LF, Henley SJ. Smoking vs other risk factors as the cause of smoking-attributable deaths: confounding in the courtroom. JAMA. 2000;284:706-712.
12. Delaney JA, Daskalopoulou SS, Brophy JM, et al. Lifestyle variables and the risk of myocardial infarction in the General Practice Research Database. BMC Cardiovasc Disord. 2007;7:38.
13. Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev. 2003;(1):CD003041.
14. American Heart Association. Heart Disease and Stroke Statistics: 2005 Update. Dallas: American Heart Association; 2004:33.
15. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
16. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final report. Bethesda, Md: National Cholesterol Education Program, National Heart, Lung, and Blood Institute, National Institutes of Health; 2002:NIH Publication No. 02-521.
17. Empana JP, Ducimetiere P, Arveiler D, et al. Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study. Eur Heart J. 2003;24:1903-1911.
18. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987-1003.
19. Wood DA, De Backer G, Faergeman O, et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J. 1998;19:1434-1503.
20. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006;332:73-78.
21. Hobbs FDR, Erhardt L. Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the Reassessing European. Attitudes about Cardiovascular Treatment (REACT) survey. Fam Pract. 2002;19:596-604.
22. Barrios V, Escobar C, Calderon A, et al. Cardiovascular risk profile and risk stratification of the hypertensive population attended by general practitioners and specialists in Spain. The CONTROLRISK study. J Hum Hypertens. 2007;21:479-485.
23. Montgomery AA, Fahey T, Mackintosh C, et al. Estimation of cardiovascular risk in hypertensive patients in primary care. Br J Gen Pract. 2000;50:127-128.
24. Kullo IJ, Malik AR. Arterial ultrasonography and tonometry as adjuncts to cardiovascular risk stratification. J Am Coll Cardiol. 2007;49:1413-1426.
25. Almahameed A. Peripheral arterial disease: recognition and medical management. Cleve Clin J Med. 2006;73:621-626,628, 632-634, passim.
26. Erbel R, Mohlenkamp S, Lehmann N, et al. Sex related cardiovascular risk stratification based on quantification of atherosclerosis and inflammation. Atherosclerosis. 2007 March 25; [Epub ahead of print].
27. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2064;350:1387-1391.
28. Klausen KP, Scharling H, Jensen JS. Very low level of microalbuminuria is associated with increased risk of death in subjects with cardiovascular or cerebrovascular diseases. J Intern Med. 2006;260:231-237.
29. Boushey CJ, Beresford SA, Omenn GS, et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 1995;274:1049-1057.
30. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022-2031.
31. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
32. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895-906.
33. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503-1516.
34. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821-828.
35. Kober L, Torp-Pedersen C, Carlsen JR, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1995;333:1670-1676.
36. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-30.
37. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685-691.
38. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med. 1992;327:669-677.
39. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.
40. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782-788.
41. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;351:2058-2068.
42. McMurray J, Solomon S, Pieper K, et al. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol. 2006;47:726-733.
43. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362:767-771.
44. Teo K, Yusuf S, Sleight P, et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J. 2004;148:52-61.
45. World Health Organization. Active Ageing. A Policy Framework. Geneva, Switzerland: World Health Organization; 2002. Available at: http://www.euro.who.int/document/hea/eactagepolframe:pdf Accessed February 6, 2008.